

Received: 2011.11.23
Accepted: 2011.11.23
Published: 2011.12.01

The impact of statin therapy on long-term cardiovascular outcomes in an outpatient cardiology practice

Authors' Contribution:

- A** Study Design
- B** Data Collection
- C** Statistical Analysis
- D** Data Interpretation
- E** Manuscript Preparation
- F** Literature Search
- G** Funds Collection

Hoang M. Lai^{1ABCDEF}, Wilbert S. Aronow^{1ACDEF}, Anthony D. Mercado^{2ABCDEF},
Phoenix Kalen^{1G}, Harit V. Desai^{1BDF}, Kaushang Gandhi^{1BDF}, Mala Sharma^{1BDF},
Harshad Amin^{1BDF}, Trung M. Lai^{1G}

¹ Department of Medicine, New York Medical College, Valhalla, NY, U.S.A

² Westchester Cardiology Associates/WestMed Medical Group and Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, U.S.A

This study was presented at the Annual Scientific Meeting of The American College of Cardiology in New Orleans, Louisiana in April, 2011

Source of support: Departmental sources

Background: Material/Methods:

Summary

Statins reduce coronary events in patients with coronary artery disease.

Chart reviews were performed in 305 patients (217 men and 88 women, mean age 74 years) not treated with statins during the first year of being seen in an outpatient cardiology practice but subsequently treated with statins. Based on the starting date of statins use, the long-term outcomes of myocardial infarction (MI), percutaneous coronary intervention (PCI), and coronary artery bypass graft surgery (CABGS) before and after statin use were compared.

Results:

Mean follow-up was 65 months before statins use and 66 months after statins use. MI occurred in 31 of 305 patients (10%) before statins, and in 13 of 305 patients (4%) after statins ($p < 0.01$). PCI had been performed in 66 of 305 patients (22%) before statins and was performed in 41 of 305 patients (13%) after statins ($p < 0.01$). CABGS had been performed in 56 of 305 patients (18%) before statins and was performed in 20 of 305 patients (7%) after statins ($p < 0.001$). Stepwise logistic regression showed statins use was an independent risk factor for MI (odds ratio=0.0207, 95% CI, 0.0082–0.0522, $p < 0.0001$), PCI (odds ratio=0.0109, 95% CI, 0.0038–0.0315, $p < 0.0001$), and CABGS (odds ratio=0.0177, 95% CI=0.0072–0.0431, $p < 0.0001$)

Conclusions:

Statin use in an outpatient cardiology practice reduces the incidence of MI, PCI, and CABGS.

key words:

statins • myocardial infarction • coronary revascularization

Full-text PDF:

<http://www.medscimonit.com/fulltxt.php?ICID=882126>

Word count:

845

Tables:

3

Figures:

–

References:

36

Author's address:

Wilbert S. Aronow, Cardiology Division, New York Medical College, Macy Pavilion, Room 138, Valhalla, NY, U.S.A.,
e-mail: wsaronow@aol.com

BACKGROUND

Numerous studies have demonstrated that statins reduce the incidence of coronary events in patients at high risk for coronary events [1–8]. The efficacy of statins in reducing coronary events in an outpatient cardiology practice needed to be investigated. This article reports data comparing the incidence of new myocardial infarction (MI), of new percutaneous coronary intervention (PCI), and of new coronary artery bypass graft surgery (CABGS) in 305 patients, mean age 74 years (93% with coronary artery disease), treated in an academic community cardiology practice during the time they were not treated with statins versus during the time they were subsequently treated with statins.

MATERIAL AND METHODS

Paper and electronics chart reviews were used to screen patients treated with statins at an academic community cardiology practice from 1978 to 2008. Based on the starting date of statin use, long-term clinical outcomes before and after statins start dates were calculated and compared. Patients who were treated with statins within the first year of follow-up were excluded from the study in order to achieve comparable duration of follow-up. Out of 1,599 patients screened at the practice [9], 305 patients met all criteria and were included in the study.

For every patient, progress notes of all interim visits, letters of correspondence, medication use, blood pressure, laboratory studies including serum lipid levels, and occurrence of adverse cardiovascular events from the time of initial presentation to the last follow-up were recorded. Adverse events included occurrence of MI, need for PCI, and need for CABGS. Drug therapy and patient comorbidities including coronary artery disease, hyperlipidemia, hypertension, diabetes mellitus, cigarette smoking history, congestive heart failure, angina, atrial fibrillation, chronic kidney disease, peripheral arterial disease, abdominal aortic aneurysm, carotid artery stenosis, transient ischemic attack, stroke, and previous MI, PCI, and CABGS were recorded. Dates of the events as well as dates of medication initiation and discontinuation were recorded. Coronary artery disease was diagnosed as previously described [10–16].

Data were extracted by the physician authors and tabulated with Microsoft Access 2003 (Microsoft Corporation, Redmond, WA, USA). Customized computer programming was written for macros within Microsoft Excel 2003. The McNemar test was used to compare clinical outcomes. Adverse events occurring before the time of initial presentation were not included in the outcomes analysis. Stepwise logistic regression was performed with MEDCAL statistical software using 48 variables listed in Tables 1 and 2 to determine if use of statins was independently associated with MI, PCI, and CABGS. A *p* value of <0.05 was considered statistically significant.

RESULTS

Table 1 shows the baseline characteristics of the 305 patients. Table 2 shows the prevalence of use of drugs in the 305 patients. Table 3 shows the incidence of MI, of PCI, and of CABGS before and after treatment with statins. Table 3 also shows levels of statistical significance.

Table 1. Baseline characteristics of 305 patients.

Age (years)	74±10
Men	217
Women	88
Follow-up before statin use (months)	65
Follow-up after statin use (months)	64
Coronary artery disease	283 (93%)
Hyperlipidemia	270 (89%)
Hypertension	251 (82%)
Diabetes mellitus	76 (25%)
Congestive heart failure	49 (16%)
Angina pectoris	35 (11%)
Atrial fibrillation	54 (18%)
Carotid artery stenosis	18 (6%)
Stroke	30 (10%)
Transient ischemic attack	18 (6%)
Chronic renal disease	8 (3%)
Peripheral arterial disease	35 (11%)
Abdominal aortic aneurysm	12 (4%)
Smoker	130 (43%)
Prior myocardial infarction	102 (33%)
Prior percutaneous coronary intervention	49 (16%)
Prior coronary artery bypass graft surgery	49 (16%)

Stepwise logistic regression analysis showed that use of statins was a significant independent predictor of new MI (odds ratio =0.0207; 95% CI, 0.0082–0.0522; *p*<0.0001), of new PCI (odds ratio =0.0109; 95% CI, 0.0038–0.0315; *p*<0.0001), and of new CABGS (odds ratio =0.0177; 95% CI, 0.0072–0.0431; *p*<0.0001).

DISCUSSION

Numerous studies have demonstrated the importance of statins in the primary and secondary prevention of cardiovascular disease [1–8,17–36]. The present study compared the incidence of new MI, of new PCI, and of new CABGS in 305 patients, mean age 74 years (93% with coronary artery disease), treated in an academic community cardiology practice during the time they were not treated with statins versus during the time they were subsequently treated with statins.

At 65-month follow-up before treatment with statins and at 64-month follow-up after treatment with statins, the incidence of new MI was significantly reduced from 10% to 4% by statins (*p*<0.01), the incidence of new PCI was significantly reduced from 22% to 13% by statins (*p*<0.01), and

Table 2. Drug therapy in 305 patients.

Medications	Number (%)	Mean duration of therapy (years)
Statins	305 (100%)	5.36
Ezetimibe	78 (26%)	2.12
Niacin	26 (9%)	2.49
Bile acid sequestrants	7 (2%)	1.12
Fibrates	34 (11%)	3.42
Fish oils	14 (5%)	1.94
Beta blockers	260 (85%)	8.06
Diuretics	180 (59%)	5.72
Angiotensin-converting enzyme inhibitors	225 (74%)	5.38
Angiotensin receptor blockers	102 (33%)	3.76
Calcium channel blockers	187 (61%)	6.29
Other antihypertensives	32 (10%)	4.73
Aspirin	270 (89%)	8.41
Ticlopidine	10 (3%)	3.18
Clopidogrel	82 (27%)	2.19
Aspirin/extended-release dipyridamole	2 (1%)	3.34
Other antiplatelet drugs	6 (2%)	2.90
Warfarin	100 (33%)	4.90
Nitrates	116 (38%)	5.26
Digoxin	70 (23%)	5.34
Cilostazol	3 (1%)	2.65
Insulin	24 (8%)	8.60
Thiazolidinediones	35 (11%)	3.08
Sulfonylureas	47 (15%)	5.37
Metformin	38 (12%)	4.55
Sitagliptin	2 (1%)	0.64

the incidence of new CABGs was significantly reduced from 18% to 7% by statins ($p < 0.001$). Stepwise logistic regression analysis using 48 variables showed that use of statins was a significant independent risk factor for reducing new MI, new PCI, and new CABGS ($p < 0.0001$).

A limitation of this study is that it is a retrospective chart analysis study with all inherent problems of such a design.

Table 3. Incidence of myocardial infarction and coronary revascularization before and after use of statins.

	Before statins	After statins	P Value
Myocardial infarction	31 (10%)	13 (4%)	< 0.01
Percutaneous coronary intervention	66 (22%)	41 (13%)	< 0.01
Coronary artery bypass graft surgery	56 (18%)	20 (7%)	< 0.001

CONCLUSIONS

Our data show that use of statins in patients with overt coronary artery disease (93%) or at high-risk for coronary artery disease in a community cardiology practice can reduce their chance of developing new MI, new PCI, and new CABGS. This study should give community practitioners, both specialists and primary care providers, the encouragement to pursue cardiovascular risk reduction strategies as a means for reducing new MI, PCI, and CABGS in their patients.

Acknowledgments

The authors wish to thank the members of Westchester Cardiology Associates in Scarsdale, New York who do not appear as authors in this paper: Stanley Epstein, M.D., Mitchell Fishbach, M.D., Gary Gabelman, M.D., Richard Grose, M.D., Douglas Hart, M.D., and Gabriela Grasa, M.D. Their superb care provided the benefits to their patients cited in this paper.

Conflicts of interest

None of the authors have any conflicts of interest.

REFERENCES:

- Miettinen TA, Pyorala K, Olsson AG et al: Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Findings from the Scandinavian Simvastatin Survival Study (4S). *Circulation*, 1997; 96: 4211–18
- Lewis SJ, Moye LA, Sacks FM et al: Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) Trial. *Ann Intern Med*, 1998; 129: 681–89
- The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med*, 1998; 339: 1349–57
- Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*, 2002; 360: 7–22
- Cannon CP, Braunwald E, McCabe CH et al: Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med*, 2004; 350: 1495–504
- LaRosa JC, Grundy SM, Waters DD et al: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med*, 2005; 352: 1425–35
- Aronow WS, Ahn C: Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > 125 mg/dL treated with statins versus no lipid-lowering drug. *Am J Cardiol*, 2002; 89: 67–69
- Szadkowska I, Stanczyk A, Aronow WS et al: Statin therapy in the elderly: a review. *Arch Gerontol Geriatr*, 2010; 50: 114–18

9. Mercado AD, Lai HM, Aronow WS et al: Reduction in atherosclerotic events through use of aggressive risk factor reduction medications: a retrospective study in an outpatient cardiology practice. *Arch Med Sci*, 2012; (in press)
10. Lai HM, Aronow WS, Rachdev A et al: Incidence of mortality in 1,040 patients with coronary heart disease or hypertensive heart disease with normal and abnormal left ventricular ejection fraction and with normal and abnormal QRS duration. *Arch Med Sci*, 2008; 4: 140-42
11. Ramdeen N, Aronow WS, Chugh S, Asija A: Patients undergoing coronary angiography because of chest pain with hepatitis C virus have a higher prevalence of obstructive coronary artery disease than a control group. *Arch Med Sci*, 2008; 4: 452-54
12. Kannam H, Aronow WS, Chilappa K et al: Association of the QRS duration on the resting electrocardiogram with the severity of coronary artery disease in 2,196 patients undergoing coronary angiography for suspected coronary artery disease. *Arch Med Sci*, 2009; 5: 163-65
13. Shao JH, Aronow WS, Ravipati G et al: Prevalence of a minimal luminal cross sectional area of coronary arteries <4 mm² determined by intravascular ultrasound in patients with coronary artery calcium scores of 0-100, 100-200, 200-300, 300-400, and >400 determined by cardiac computer tomography. *Arch Med Sci*, 2009; 5: 172-74
14. Shen X, Aronow WS, Nair CK et al: Thoracic aortic atheroma severity predicts high-risk coronary anatomy in patients undergoing transesophageal echocardiography. *Arch Med Sci*, 2011; 7: 61-66
15. Aronow WS: Osteoporosis, osteopenia, and atherosclerotic vascular disease. *Arch Med Sci*, 2011; 7: 21-26
16. Duncan KA, Sukhija R, Aronow WS et al: Systolic compression of left main coronary artery by left ventricular pseudoaneurysm complicated by critical stenosis. *Arch Med Sci*, 2012; (in press)
17. Angelopoulos J, Krassakopoulos N, Nathanson R et al: Co-administration of ezetimibe and a statin in management of dyslipidemias: a meta-analysis of clinical trials. *Arch Med Sci*, 2009; 5: 347-63
18. Delavari A, Kelishadi R, Forouzanfar MH et al: The first cut-off points for generalized and abdominal obesity in predicting lipid disorders in a nationally representative population in the Middle East: The National Survey of Risk Factors for Non-Communicable Diseases of Iran. *Arch Med Sci*, 2009; 5: 542-49
19. Diakou M, Miltiadous G, Xenophontos S et al: Characterization of low density lipoprotein receptor (LDLR) gene mutations in Albania. *Arch Med Sci*, 2010; 6: 198-200
20. Gordon L, Ragoobirsingh D, Morrison E et al: Dyslipidemia in hypertensive obese type 2 diabetic patients in Jamaica. *Arch Med Sci*, 2010; 6: 701-8
21. Katsiki N, Mikhailidis DP, Athyros VG et al: Are we getting to lipid targets in real life? *Arch Med Sci*, 2010; 6: 639-41
22. Mark L, Paragh G, Karadi I et al: Changes in attainment of lipid goals by general practitioners and specialists in patients at high cardiovascular risk in Hungary during 2004-2008. *Arch Med Sci*, 2010; 6: 695-700
23. Pavlidis AN, Kolovou GD, Anagnostopoulou KK et al: Postprandial metabolic heterogeneity in men with primary dyslipidaemia. *Arch Med Sci*, 2010; 6: 879-86
24. Ravipati G, Aronow WS, Kumbar S et al: Patients with diabetes with ischemic stroke have a higher hemoglobin A1c level and a higher serum low-density lipoprotein cholesterol level than diabetics without ischemic stroke. *Arch Med Sci*, 2009; 5: 391-93
25. Vulic D, Loncar S, Krneta M et al: Risk factor control and adherence to treatment in patients with coronary heart disease in the Republic of Srpska, Bosnia and Herzegovina in 2005-2006. *Arch Med Sci*, 2010; 6: 270-75
26. Wainwright G, Mascitelli L, Goldstein MR: Cholesterol-lowering therapy and cell membranes. Stable plaque at the expense of unstable membranes? *Arch Med Sci*, 2009; 5: 289-95
27. Wozniak B, Wozniak A, Drewa G et al: The effect of treatment on lipid peroxidation in patients with subarachnoid haemorrhage. *Arch Med Sci*, 2009; 5: 394-400
28. Xu M, Yuan G, Wei F: Effect of atorvastatin in patients with chronic heart failure-insights from randomized clinical trials. *Arch Med Sci*, 2010; 6: 866-73
29. Haleagrahara N, Yee TM, Chakravarthi S, Lee N: Protective effect of N-acetylcysteine on cyclosporine A-induced changes in lipid hydroperoxide levels and renal dysfunction in rats. *Arch Med Sci*, 2009; 5: 16-22
30. Kedziora-Kornatowska K, Czuczajko J, Motyl J et al: Effects of coenzyme Q10 supplementation on activities of selected antioxidative enzymes and lipid peroxidation in hypertensive patients treated with indapamide. A pilot study. *Arch Med Sci*, 2010; 6: 513-18
31. Mujib M, Desai R, Levitan EB et al: Prospective population studies of incident heart failure without data on baseline left ventricular ejection fraction. *Arch Med Sci*, 2010; 6: 686-88
32. Katsiki N, Mikhailidis DP, Banach M: Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. *J Hypertens*, 2011; 29: 2493-94
33. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J: Time for new indications for statins? *Med Sci Monit*, 2009; 15(12): MS1-5
34. Stepien M, Banach M, Mikhailidis DP et al: Role and significance of statins in the treatment of hypertensive patients. *Curr Med Res Opin*, 2009; 25: 1995-2005
35. Desai H, Aronow WS, Ahn C et al: Incidence of perioperative myocardial infarction and of 2-year mortality in 577 elderly patients undergoing noncardiac vascular surgery treated with and without statins. *Arch Gerontol Geriatr*, 2010; 51: 149-51
36. Aronow HD, Hess G, Hill J et al: Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol. *Am J Therap*, 2010; 17: 167-75